




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/69, 401/14, 401/12, 403/10, A61K 31/505		A1	(11) International Publication Number: WO 96/19459
			(43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/EP95/04843		(74) Agents: GROSSNER, Lutz et al.; P.O. Box 3255, CH-4002 Basle (CH).	
(22) International Filing Date: 8 December 1995 (08.12.95)			
(30) Priority Data: 3837/94-6 20 December 1994 (20.12.94) CH 2419/95-1 24 August 1995 (24.08.95) CH		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(71) Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4002 Basle (CH).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BREU, Volker [DE/DE]; Belchenstrasse 7, D-79418 Schliengen (DE). BURRI, Kaspar [CH/CH]; Höhenweg 47, CH-4102 Binningen (CH). CASSAL, Jean-Marie [FR/FR]; 4, rue du Markstein, F-68100 Mulhouse (FR). CLOZEL, Martine [FR/FR]; 11, rue Oberlin, F-68300 Saint-Louis (FR). HIRTH, Georges [FR/FR]; 7, rue de l'Ancre, F-68330 Huningue (FR). LÖFFLER, Bernd-Michael [DE/DE]; Seilhof 21, D-79206 Oberrimsingen (DE). MÜLLER, Marcel [CH/CH]; Quellenweg 10, CH-4402 Frenkendorf (CH). NEIDHART, Werner [DE/FR]; 5, rue du Jura, F-68870 Bartenheim (FR). RAMUZ, Henri [CH/CH]; Rheinparkstrasse 3, CH-4127 Birsfelden (CH).		Published With international search report.	

(54) Title: NOVEL SULFONAMIDES



(57) Abstract

Compounds of formula (I) wherein R^1 - R^8 , A and B have the significance given in the description, are endothelin inhibitors and can be used for the treatment of disorders which are associated with endothelin activities, such as high blood pressure.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

Novel Sulfonamides

The present invention is concerned with novel sulphonamides and their use as medicaments. In particular, the invention is concerned with novel compounds of the formula



10

wherein

R¹

signifies aryl or heterocyclyl;

R²

signifies tetrazolyl, lower-alkyl-substituted tetrazolyl, cyano, carboxy, lower-alkoxycarbonyl, hydroxymethyl, formyl, carbamoyl, thiocarbamoyl, amidino or hydroxyamidino;

15

R³signifies a residue -O-(CR^aR^b)_n-OR⁹;R⁴-R⁸

signify hydrogen, lower-alkoxy or halogen;

R⁹signifies hydrogen, aryl, lower-aralkyl, heterocyclyl or a residue -C(O)NHR¹⁰;

20

R¹⁰

signifies lower-alkyl, phenyl, substituted phenyl, pyridyl or substituted pyridyl;

R^a and R^b

signify hydrogen or lower-alkyl;

n

signifies 2, 3 or 4; and

25

A and B

signify CH; or one of the symbols A or B signifies nitrogen and the other signifies CH; or

R²

signifies hydrogen and one of the symbols A or B signifies N-oxide (N→O) and the other signifies CH,

and pharmaceutically usable salts of compounds of formula I.

30

Examples of aryl residues are phenyl and substituted phenyl residues, with esp. halogen, lower-alkyl, lower-alkoxy, lower-alkylenedioxy, carboxyl and trifluoromethyl coming into consideration as substituents. Lower-aralkyl signifies lower alkyl residues substituted by aryl, e.g. phenyl or substituted phenyl,

35

preferably benzyl. Examples of heterocyclyl residues are residues of mono- or bicyclic, 5- and 6-membered heterocycles having oxygen, nitrogen or sulphur as the hetero atom, such as 2- and 3-furyl, 2-, 4- and 5-pyrimidinyl, 2-, 3- and 4-pyridyl, 1,2- and 1,4-diazinyl, 2- and 3-thienyl, oxazolyl, thiazolyl, imidazolyl, benzofuranyl, benzothienyl, purinyl, quinolyl, isoquinolyl and quinazolyl, which residues can be substituted, e.g. by 1 or 2 lower-alkyl groups. Preferably, heterocyclyl is a pyridyl residue or a substituted pyridyl residue.

10


The term "lower" used here denotes groups with 1-7 C atoms, preferably 1-4 C atoms. Alkyl and alkoxy groups can be straight-chain or branched. Methyl, ethyl, propyl, isopropyl, butyl, sec. and tert.butyl are examples of such alkyl groups.

15 Halogen denotes fluorine, chlorine, bromine and iodine, with chlorine being preferred.

A preferred group of compounds of formula I comprises those in which A and B are CH or one of the symbols A and B is nitrogen. R¹ is preferably a phenyl residue, which is mono- or di-substituted, or a pyridyl residue, which is mono-substituted by alkyl, especially an alkyl-substituted 2-pyridyl residue. R² is preferably a tetrazolyl residue. R³ is preferably -O(CH₂)_nOH, -O(CH₂)_nO-benzyl or -O(CH₂)_nOC(O)NHR¹⁰, in which R¹⁰ is pyridyl, especially 2-pyridyl. n is preferably 2. Of particular interest among these compounds are those in which R⁴ is lower-alkoxy and R⁵-R⁸ are hydrogen; or R⁴ is halogen, R⁷ is lower-alkoxy and R⁵, R⁶ and R⁸ are hydrogen; A is nitrogen and B is CH.

30 The compounds of formula I can be manufactured by

a) reacting a compound of formula II




II

35

wherein R^{12} is 3- or 4-cyanophenyl or 2- or 4-pyridyl N-oxide and Hal is halogen and the remaining symbols have the significance set forth above,

with a compound of the formula $MO-(CR^aR^b)_n-OR^{91}$, wherein M is an alkali metal and R^{91} is hydrogen, aryl, lower-alkyl or heterocyclyl and R^a , R^b and n have the significance set forth above; or

b) reacting a compound of formula III



wherein R^{11} is 2- or 4-pyridyl N-oxide and the remaining symbols have the significance set forth above,

with a trialkylsilyl cyanide and a trialkylamine; or

c) reacting a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above with an azide in the presence of an aprotic Lewis acid; or

d) converting a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above with an alkali metal alcoholate and thereafter with hydrazine into the corresponding amidrazone and treating this with a nitrite and an acid; or

e) reacting a compound of formula I in which R^9 is hydrogen with an isocyanate of the formula $R^{10}NCO$; or

f) transforming the cyano group in a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxyamidino group; or

g) alkylating the tetrazolyl group in a compound of formula I in which R^2 is tetrazolyl and R^9 is aryl, lower-alkyl or heterocyclyl and cleaving off a hydroxy protecting group from the reaction product;

5

and, if desired, converting a compound of formula I obtained into a salt.

The reaction of a compound of formula II with a compound
10 of the formula $MO(CR^aR^b)_nOR^{91}$ (process variant a) is conveniently carried out in a glycol corresponding to this compound as the solvent, e.g. in ethylene glycol when $n = 2$ and R^a and R^b are hydrogen. The alkali metal M is preferably sodium and Hal is preferably chlorine. The reaction is conveniently carried out
15 while heating, e.g. to 40-100°C. According to this process variant there are obtained compounds of formula I in which R^2 signifies cyano and A and B signify CH; or R^2 signifies hydrogen and one of the symbols A or B signifies N-oxide and the other signifies CH, and R^9 is a residue R^{91} as defined above, and the remaining
20 symbols have the given significance.

In process variant b) a N-oxide of formula II is preferably reacted with trimethylsilyl cyanide and triethylamine. The reaction is conveniently carried out in acetonitrile while heating
25 to the reflux temperature of the reaction mixture. According to this process variant there are obtained compounds of formula I in which R^2 signifies cyano and one of the symbols A or B signifies nitrogen and the other signifies CH and the remaining symbols have the given significance.

30

In the reaction according to process variant c) there can be used as the azide e.g. sodium azide, guanidinium azide or trimethylsilyl azide. Ammonium salts, e.g. ammonium chloride, can be used as Lewis acids. The reaction can be carried out in an
35 aprotic, polar solvent such as dimethylformamide or dimethyl sulphoxide, conveniently while heating, e.g. to a temperature of 60-100°C.

The reaction of a compound of formula I in which R² is cyano with hydrazine according to process variant d) proceeds via the iminoether, from which the amidrazone, i.e. a compound corresponding to formula I with R² = -CH(NH)NHNH₂, is obtained with excess hydrazine. The amidrazone is converted by nitro-
sation into an iminoazide which cyclizes spontaneously to the tetrazole. According to process variants c) and d) there are obtained compounds of formula I in which R² signifies tetrazolyl and the remaining symbols have the given significance.

The reaction in accordance with process variant e) can be effected in a manner known per se for the preparation of carbamates from alcohols and isocyanates, e.g. in a suitable anhydrous organic solvent, e.g. a hydrocarbon such as toluene, conveniently while heating. The isocyanate can be generated in situ, e.g. from an azide of the formula R¹⁰CON₃ by thermal rearrangement. According to this process variant there are obtained compounds of formula I in which R⁹ signifies a residue -C(O)NHR¹⁰ and the remaining symbols have the given
significance.

The transformation of a cyano group R² in a compound of formula I into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxy-amidino group in accordance with process variant f) can be effected in a manner known per se for such transformations. For example, the cyano group can be converted by treatment with alkali alcoholate, e.g. with sodium methylate in methanol, into an iminoether (i.e., the group C(NH)OCH₃) which can be converted in situ by treatment with hydrochloric acid into an alkyl carboxylate (e.g. the group -COOCH₃), which can be saponified to the carboxylic acid by treatment with alcoholic alkali. Alternatively, the iminoether, obtained in situ, can be transformed by treatment with ammonium chloride in methanol into the corresponding amidino compound (R² = amidino) and this can be transformed by treatment with aqueous alkali and subsequent acidification into the corresponding carbamoyl compound (R² = -C(O)NH₂). By treatment of the iminoether, obtained in situ, with hydroxyl-

amine and aqueous sodium acetate solution there can be obtained the corresponding hydroxyamidino compounds ($R^2 = -C(NH)NHOH$). A carboxy group can be reduced by treatment with reducing agents such as sodium dihydro-bis-(2-methoxyethoxy)aluminate in
5 toluene to the hydroxymethyl group and this can be oxidized to the formyl group by treatment with oxidizing agents such as manganese dioxide. In these reaction sequences R^3 should not contain a hydroxy group, i.e. R^9 should not represent hydrogen, but should represent e.g. benzyl.

10

The alkylation of a compound of formula I in accordance with process variant g) can be carried out in a manner known per se, e.g. by treatment with a lower-alkyl halide in the presence of a base such as K tert.-butylate in tetrahydrofuran, whereby a
15 thus-obtained mixture of 1- and 2-lower-alkyl-tetrazolyl compounds of formula I can be separated in a manner known per se, e.g. by chromatography. Suitable hydroxy protecting groups are e.g. alkylsilyl protecting groups such as dimethyl-tert.-butylsilyl and tetrahydropyranyl, which can be introduced and
20 cleaved off from the reaction product in a manner known per se. According to process variant g) there are accordingly obtained compounds of formula I in which R^2 represents a lower-alkyl-tetrazolyl residue and R^9 represents hydrogen.

25 The compounds of formula I which contain a carboxy or tetrazolyl group can be converted in a manner known per se into pharmaceutically usable salts, e.g. alkali salts such as Na and K salts or alkaline earth metal salts such as Ca or Mg salts or salts with amines such as monoethanolamine.

30

The compounds which are used as starting materials, insofar as they are not known or their preparation is described hereinafter, can be prepared in analogy to known methods or to methods described below.

35

The compounds of formula I given above are endothelin receptor inhibitors. They can therefore be used for the treatment of disorders which are associated with endothelin activities,

especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.

The inhibitory activity of the compounds of formula I on
5 endothelin receptors can be demonstrated using the test procedures described hereinafter:

I: Inhibition of endothelin binding to recombinant ET_A receptors

10 A cDNA coding for human ET_A receptors of human placenta was cloned (M. Adachi, Y.-Y. Yang, Y. Furuichi and C. Miyamoto, BBRC 180, 1265-1272) and expressed in the baculovirus-insect cell system. Baculovirus-infected insect cells from a 23 l fermenter are centrifuged off (3000 x g, 15 minutes, 4°C)
15 60 hours after the infection, re-suspended in Tris buffer (5 mM, pH 7.4, 1 mM MgCl₂) and again centrifuged. After a further re-suspension and centrifugation the cells are suspended in 800 ml of the same buffer and freeze-dried at -120°C. The cells disintegrate when the suspension in this hypotonic buffer
20 mixture is thawed. After a repeated freeze-drying/thawing cycle the suspension is homogenized and centrifuged (25000 x g, 15 minutes, 4°C). After suspension in Tris buffer (75 mM, pH 7.4, 25 mM MgCl₂, 250 mM sucrose) 1 ml aliquots (protein content about 3.5 mg/ml) are stored at -85°C.

25

For the binding assay, the freeze-dried membrane preparations are thawed and, after centrifugation at 20°C and 25000 g for 10 minutes, re-suspended in assay buffer (50 mM Tris buffer, pH 7.4, containing 25 mM MnCl₂, 1 mM EDTA and 0.5%
30 bovine serum albumin). 100 µl of this membrane suspension containing 70 µg of protein are incubated with 50 µl of [¹²⁵I]-endothelin (specific activity 2200 Ci/mMol) in assay buffer (25000 cpm, final concentration 20 pM) and 100 µl of assay buffer containing varying concentrations of test compound. The
35 incubation is carried out at 20°C for 2 hours or at 4°C for 24 hours. The separation of free and membrane-bound radio-ligands is carried out by filtration over a glass fibre filter. The inhibitory activity of compounds of formula I determined in this

test procedure is given in Table 1 as the IC₅₀, i.e. as the concentration [nM] which is required to inhibit 50% of the specific binding of ¹²⁵I-endothelin.

5

Table 1

Compound of Example	IC ₅₀ [nM]
4	6
29	4
35	2
36	8
40	8
41	1

11. Inhibition of endothelin-induced contractions in isolated rat aorta rings

10

Rings with a length of 5 mm were cut out from the thorax aorta of adult Wistar-Kyoto rats. The endothelium was removed by lightly rubbing the internal surface. Each ring was immersed at 37°C in 10 ml of Krebs-Henseleit solution in an isolated bath while gassing with 95% O₂ and 5% CO₂. The isometric stretching of the rings was measured. The rings were stretched to a pre-tension of 3 g. After incubation for 10 minutes with the test compound or vehicle cumulative dosages of endothelin-1 were added. The activity of the test compound was ascertained by the observed shift to the right of the dosage-activity curve of endothelin-1 in the presence of different concentrations of antagonist. This shift to the right (or "dose ratio", DR) corresponds to the quotient from the EC₅₀ values of endothelin-1 in the presence and in the absence of antagonist, with the EC₅₀ value denoting the endothelin concentration required for a half-maximum contraction.

The corresponding pA₂ value, which is a measure of the activity of the test compound, was calculated using a computer programme according to the following equation from the "dose ratio" DR for each individual dosage-activity curve.

30

$$pA_2 = \log(DR-1) - \log(\text{antagonist-concentration})$$

The EC₅₀ of endothelin in the absence of test compounds is
5 0.3 nM.

The pA₂ values obtained with compounds of formula I are
given in Table 2.

Table 2

Compound of Example	Dose ratio (switch to the right)
4	9.60
29	10.0
35	9.8
36	9.4
40	10.2
41	10.6

10

On the basis of their capability of inhibiting endothelin
binding, the compounds of formula I can be used as medicaments
for the treatment of disorders which are associated with vaso-
constriction of increasing frequencies. Examples of such
15 disorders are high blood pressure, coronary disorders, cardiac
insufficiency, renal and myocardial ischaemia, renal insuffici-
ency, dialysis, cerebral ischaemia, cerebral infarct, migraine,
subarachnoid haemorrhage, Raynaud syndrome and pulmonary high
pressure. They can also be used in atherosclerosis, the preven-
20 tion of restenosis after balloon-induced vascular dilation,
inflammations, gastric and duodenal ulcers, ulcus cruris, gram-
negative sepsis, shock, glomerulonephritis, renal colic,
glaucoma, asthma, in the therapy and prophylaxis of diabetic
complications and complications in the administration of cyclo-
25 sporin, as well as other disorders associated with endothelin
activities.

The compounds of formula I can be administered orally,
rectally, parentally, e.g. intravenously, intramuscularly,

subcutaneously, intrathecally or transdermally; or sublingually or as ophthalmological preparations, or as an aerosol. Capsules, tablets, suspensions or solutions for oral administration, suppositories, injection solutions, eye drops, salves or spray solutions are examples of administration forms.

Intravenous, intramuscular or oral administration is a preferred form of use. The dosages in which the compounds of formula I are administered in effective amounts depend on the nature of the specific active ingredient, the age and the requirements of the patient and the mode of administration. In general, dosages of about 0.1-100 mg/kg body weight per day come into consideration. The preparations containing the compounds of formula I can contain inert or also pharmacodynamically active additives. Tablets or granulates e.g. can contain a series of binders, fillers, carriers or diluents. Liquid preparations can be present, for example, in the form of a sterile water-miscible solution. Capsules can contain a filler or thickener in addition to the active ingredient. Furthermore, flavour-improving additives as well as substances usually used as preserving, stabilizing, moisture-retaining and emulsifying agents as well as salts for varying the osmotic pressure, buffers and other additives can also be present.

The previously mentioned carrier materials and diluents can comprise organic or inorganic substances, e.g. water, gelatine, lactose, starch, magnesium stearate, talc, gum arabic, polyalkylene glycols and the like. It is a prerequisite that all adjuvants used in the manufacture of the preparations are non-toxic.

The following Examples illustrate the invention in more detail. DMF denotes dimethylformamide, THF denotes tetrahydrofuran and EtOAc denotes ethyl acetate.

Example 1

- a) 200 ml of dimethoxyethane and 110.9 g of 4-[4-(4-tert-butyl-phenyl-sulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide are added all at once to a solution of 23.80 g of sodium in 660 ml of ethylene glycol. The solution is heated at 90°C for 20 hours while stirring, thereafter cooled, poured into 2500 ml of H₂O and thereafter treated with CH₃COOH to pH 5. The mixture is extracted three times with EtOAc, the organic phase is washed with H₂O, dried with Na₂SO₄ and evaporated under reduced pressure. The residue is recrystallized from CH₃CN and thereafter twice from a mixture of acetone and CH₃CN. There is thus obtained 4-[4-(4-tert-butyl-phenyl-sulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide.

Preparation of the starting material:

- b) 53.1 g of 4-cyano-pyridine (98%) are added all at once to a solution of 1.15 g of sodium in 200 ml of abs. MeOH. After 6 hours 29.5 g of NH₄Cl are added while stirring vigorously. The mixture is stirred at room temperature overnight. 600 ml of ether are added thereto, whereupon the precipitate is filtered off under suction and thereafter dried at 50°C under reduced pressure. There is thus obtained 4-amidino-pyridine hydrochloride (decomposition point 245-247°C).
- c) 112.9 g of diethyl (2-methoxyphenoxy)malonate are added dropwise within 30 minutes to a solution of 27.60 g of sodium in 400 ml of MeOH. Thereafter, 74.86 g of the amidine hydrochloride obtained in b) are added all at once. The mixture is stirred at room temperature overnight and evaporated at 50°C under reduced pressure. The residue is treated with 500 ml of ether and filtered off under suction. The filter cake is dissolved in 1000 ml of H₂O and treated little by little with 50 ml of CH₃COOH. The precipitate is filtered off under suction, washed with 400 ml of H₂O and dried at 80°C under reduced pressure.

There is thus obtained 5-(2-methoxy-phenoxy)-2-(pyridin-4-yl)-pyrimidine-4,6-diol (or tautomer), melting point above 250 C.

d) A suspension of 154.6 g of 5-(2-methoxy-phenoxy)-2-(pyridin-4-yl)-pyrimidine-4,6-diol (or tautomer) in 280 ml of POCl_3 is heated at 120°C in an oil bath for 24 hours while stirring vigorously. The reaction mixture changes gradually into a dark brown liquid which is evaporated under reduced pressure and thereafter taken up three times with 500 ml of toluene and evaporated. The residue is dissolved in 1000 ml of CH_2Cl_2 , treated with ice and H_2O and thereafter adjusted with 3N NaOH until the aqueous phase has pH 8. The organic phase is separated and the aqueous phase is extracted twice with CH_2Cl_2 . The combined CH_2Cl_2 extracts are dried with MgSO_4 , evaporated to half of the volume, treated with 1000 ml of acetone and the CH_2Cl_2 remaining is distilled off at normal pressure. After standing in a refrigerator for 2 hours the crystals are filtered off under suction and dried at 50°C overnight. There is thus obtained 4,6-dichloro-5-(2-methoxy-phenoxy)-2-pyridin-4-yl)-pyrimidine, melting point 178-180°C.

e) A solution of 17.4 g of 4,6-dichloro-5-(2-methoxy-phenoxy)-2-pyridin-4-yl)-pyrimidine in 100 ml of CH_3CN is boiled at reflux for 3 hours with 15 ml of a 32% peracetic acid solution, thereafter cooled and stored in a refrigerator overnight. The crystals are filtered off under suction and dried at 50°C under reduced pressure. There is thus obtained 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide, melting point 189-190°C.

f) A solution of 36.4 g of 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide and 52.8 g of p-tert-butylphenyl-sulphonamide potassium in 150 ml of abs. DMF is stirred at room temperature for 24 hours. Thereafter, it is poured into a mixture of 1500 ml of H_2O and 1000 ml of ether while stirring mechanically, whereby a precipitate forms. The suspension is adjusted to pH 5 with CH_3COOH , suction filtered, the crystals are washed with cold water and thereafter with

ether and dried at 50°C. There is thus obtained 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide as a colourless material of melting point 247-249°C.

5

Example 2

A solution of 78.45 g of 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide, 122.5 g of trimethylsilyl cyanide, 127.8 g of triethylamine and 1200 ml of CH₃CN is boiled at reflux for 20 hours and thereafter evaporated under reduced pressure. The oily residue is taken up in 1000 ml of EtOAc and the solution is washed with CH₃COOH:H₂O 9:1 and then with H₂O. The EtOAc extracts are dried with Na₂SO₄. After evaporation of the solvent the residue is taken up in a mixture of CH₃CN and CF₃COOH (20:1), whereby a crystalline precipitate separates. There is thus obtained 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide of melting point 176-179°C.

Example 3

A suspension of 50.0 g of 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide, 46.33 g of NH₄Cl and 56.47 g of NaN₃ in 1600 ml of DMF is heated to 70°C for 24 hours while stirring vigorously. The majority of the solvent is distilled off under reduced pressure, the residue is dissolved in H₂O, the solution is extracted four times at pH 6.5 with ether, thereafter treated with CH₃COOH to pH = 4.5 and extracted with EtOAc. After working up there is obtained a residue which is treated with ether and filtered off under suction therefrom. There is thus obtained 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide, melting point 225-227°C.

Example 4

- a) To a solution, heated to 90°C, of 46.0 g of 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide in 600 ml of abs. dioxan is added dropwise within 60 minutes while stirring a cold solution of 22.0 g of 2-pyridyl-carbonyl azide in 200 ml of dioxan. After 4 hours the solvent is evaporated under reduced pressure, the residue is taken up in 300 ml of EtOAc and left to stand at room temperature overnight. The crystalline mass is filtered off under suction and washed with EtOAc. After repeated recrystallization from tetrahydrofuran and EtOAc and drying under reduced pressure firstly at 45°C for 3 days and thereafter at 65°C for a further 2 days there is obtained 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl-oxy]-ethyl pyridin-2-ylcarbamate, melting point from 214°C with very slow decomposition.
- b) The 2-pyridyl-carbonyl azide used as the starting material can be prepared as follows:

A solution of 53.9 g of 2-picolinic acid in 330 ml of abs. DMF and 61.2 ml of triethylamine is treated dropwise within 30 minutes at 10°C with 99.7 ml of diphenylphosphoryl azide. After 2 hours at room temperature the solution is evaporated for the most part at 30°C under reduced pressure, the oily residue is treated with 200 ml of a 5% sodium bicarbonate solution and exhaustively extracted with ether. The ethereal extracts are combined, dried with MgSO₄ and evaporated at room temperature under reduced pressure. The yellowish oily residue is cooled in an ice bath at 0-5°C and the crystals are washed at -20°C with a 1:1 mixture of ether and hexane. There is thus obtained 2-pyridyl-carbonyl azide as colourless crystals of melting point 39-41°C.

Example 5

A solution of 47.8 g of 2-[6-(4-tert-butyl-phenylsulphonyl-amino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate in 500 ml of abs. THF is treated dropwise with a cold solution of 2.8 g of sodium in 50 ml of methanol, whereby there forms gradually a solid precipitate which, after stirring at room temperature for 1 hour, is filtered off under suction, dried under greatly reduced pressure at 35°C for 3 days and thereafter at 50°C for 2 days. There is thus obtained the bis-sodium salt, decomposition point above 250°C.

Example 6

15

The same tetrazole as in Example 3 is obtained starting from the same starting material as in Example 3 in a one-pot reaction (3 steps) under the following conditions:

20 2.4 ml of a 1.0N sodium methylate solution are added at room temperature to a suspension of 1.15 g (2 mmol) of 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide in 50 ml of abs. MeOH. The clear yellowish solution which results therefrom is held at 40°C for 3 days.

30 The solution of the iminoether is slowly added dropwise at room temperature within 30 minutes to a suspension of 302 mg (4.4 mmol) of $\text{H}_2\text{N}-\text{NH}_2 \cdot \text{HCl}$ in 10 ml of abs. MeOH, whereby a crystalline precipitate separates gradually. The suspension is cooled to 2°C while stirring further and treated with 15 ml of 1.0N HCl. The clear yellowish solution (pH = 1.7) is treated dropwise with a solution of 800 mg (11.6 mmol) of NaNO_2 in 10 ml of H_2O in such a manner that the temperature does not exceed 5°C (pH 2.7). After 1 hour a further 2 ml of 1N HCl are added and then a solution of 200 mg (2.9 mmol) of NaNO_2 in 2 ml of H_2O is added. The solution is left at room temperature for 2 hours, the MeOH is evaporated under reduced pressure and the

suspension remaining behind is extracted with EtOAc. The combined EtOAc solutions are firstly washed twice with H₂O and thereafter carefully extracted with a 0.5N NaHCO₃-H₂O solution. The combined aqueous (NaHCO₃) solutions are carefully treated
5 with 3N HCl (to pH = 2) and the suspension is extracted with EtOAc as usual. After evaporation of the solvent under reduced pressure there is obtained a crystalline residue which is identical with the product obtained in Example 3.

10

Example 7

a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and Na glycolate in ethylene glycol there is
15 obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide, melting point 110-112°C (from EtOAc).

b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

25

Example 8

a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide, melting point
30 172-173°C (from EtOAc).

b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained
35 N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-

methoxy-phenoxy)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide.

Example 9

5 a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide as a white
10 solid.

b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonic acid there is
15 obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide.

20 Example 10

a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide,
25 melting point 146-150°C (from acetonitrile).

b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide there
30 is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide.

35

Example 11

- a) In analogy to Example 1a), from 1,3-benzodioxol-5-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 174-175°C (from acetonitrile).
- b) In analogy to Example 2, from 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.

Example 12

- a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide, melting point 189-191°C (from EtOAc).
- b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide.

Example 13

- a) In analogy to Example 1a), from N-[6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-

yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide as a white solid.

b) In analogy to Example 2, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide.

10

Example 14

a) In analogy to Example 1a), from pyridine-3-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 227-228°C (from EtOAc).

b) In analogy to Example 2, from pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.

25

Example 15

a) In analogy to Example 1a), from 5-methyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 188-190°C (from acetonitrile).

b) In analogy to Example 2, from 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-

35

(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.

Example 16

5

a) In analogy to Example 1a), from 5-isopropyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 140-141°C (from EtOAc).

b) In analogy to Example 2, from 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide.

20

Example 17

a) In analogy to Example 1a), from 4-tert-butyl-N-[6-chloro-5-(2-chloro)-5-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide, melting point 228-230°C (from EtOAc).

b) In analogy to Example 2, from 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide.

35

Example 18

a) In analogy to Example 1a), from 1,3-benzodioxol-4-sulphonic acid 6-chloro-5-(2-chloro-5-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 208-210°C (from EtOAc).

b) In analogy to Example 2, from 1,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide.

Example 19

a) In analogy to Example 1a), from 5-isopropyl-pyridine-2-sulphonic acid-6-chloro-5-(2-chloro-5-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid-5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide, melting point 204-206°C (from EtOAc).

b) In analogy to Example 2 from 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide.

Example 20

a) In analogy to Example 1a), from 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-

methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide as an amorphous substance.

b) In analogy to Example 2 from 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained 4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

10 Example 21

In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide as a white substance of melting point 205-207°C from acetonitrile.

Example 22

20 In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide as
25 a white substance of melting point 214-216°C from CH₃CN.

Example 23

In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide
30 as a white substance of melting point 218-220°C from acetonitrile.
35

Example 24

In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzene-sulphonamide as a white substance.

10 Example 25

In analogy to Example 3, from 1,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamid there is obtained 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 227-229°C from CH₃CN.

20 Example 26

In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide as a white substance of melting point 224-225°C from acetonitrile.

30 Example 27

In analogy to Example 3, from N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide there is obtained N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzenesulphonamide as a white substance.

Example 28

In analogy to Example 3, from pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance.

10

Example 29

In analogy to Example 3, from 5-methyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 239-241°C from CH₃CN.

20

Example 30

In analogy to Example 3, from 5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide as a white substance of melting point 198-200°C from acetonitrile. The corresponding disodium salt is obtained as a white powder from this product using sodium methylete in analogy to Example 5.

30

Example 31

In analogy to Example 3, from 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-

35

benzenesulphonamide of melting point 170-172 C from CH₃CN. The corresponding disodium salt is obtained as a white powder from this product using sodium methylate in analogy to Example 5.

5

Example 32

In analogy to Example 3, from 1,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-
10 6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide there is obtained 1,3-benzodioxol-5-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide.

15

Example 33

In analogy to Example 3, from 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide there
20 is obtained 5-isopropyl-pyridine-2-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide.

Example 34

25

In analogy to Example 3, from 4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-
30 (1H-tetrazol-5-yl)-pyridin-2-yl]-pyrimidin-4-yl]-benzenesulphonamide of melting point 248-251°C (with decomposition) from CH₂Cl₂ + CH₃CN.

Example 35

35

In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and 2-pyridyl-carbonyl

azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-phenylsulphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate as a white substance.

5

Example 36

In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide and 2-pyridyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate as a white substance of melting point 224-225°C from CH₃CN.

15

Example 37

In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzenesulphonamide and 3,4-methylenedioxy-phenyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methylphenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate of melting point 198-199°C from CH₃CN.

25

Example 38

In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide and 2-pyridyl-carbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of melting point 224-225°C from EtOAc.

35

Example 39

In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-

- pyrimidin-4-yl]-4-methoxy-benzenesulphonamide and 3,4-methylenedioxy-phenylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate of melting point 198-200°C from EtOAc.

Example 40

- 10 In analogy to Example 4, from N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide and 2-pyridylcarbonyl azide there is obtained 2-[5-(2-methoxy-phenoxy)-6-(4-methylsulphanylphenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.

Example 41

- 20 In analogy to Example 4, from 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 2-pyridylcarbonyl azide there is obtained 2-[6-(1,3-benzodioxol-5-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of melting point 194-196°C from EtOAc.

Example 42

- 30 In analogy to Example 4, from 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 3,4-methylenedioxy-phenylcarbonyl azide there is obtained 2-[6-(1,3-benzodioxol-5-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate of melting point 187-188°C from EtOAc.

Example 47

In analogy to Example 4, from 5-methyl-pyridine-2-
5 sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-
(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 2-
pyridylcarbonyl azide there is obtained 2-[5-(2-methoxy-
phenoxy)-6-(5-methyl-pyridin-2-ylsulphonylamino)-2-(2-1H-
tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-
10 ylcarbamate.

Example 48

In analogy to Example 4 from 5-isopropyl-pyridine-2-
15 sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-
(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 2-
pyridylcarbonyl azide there is obtained 2-[6-(5-isopropyl-
pyridin-2-ylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-
tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-
20 ylcarbamate.

Example 49

In analogy to Example 4, from 5-isopropyl-pyridine-2-
25 sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-
(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide and 3,4-
methylenedioxy-phenyl-carbonyl azide there is obtained 2-[6-(5-
isopropyl-pyridin-2-ylsulphonylamino)-5-(2-methoxy-phenoxy)-
2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl
30 1,3-benzodioxol-5-ylcarbamate.

Example 50

In analogy to Example 4, from 4-tert-butyl-N-[5-(2-chloro-
35 5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-
yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide and 2-
pyridylcarbonyl azide there is obtained 2-[6-(4-tert-butyl-
phenylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-

1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl
pyridin-2-ylcarbamate.

Example 51

5 In analogy to Example 4, from 1,3-benzodioxol-5-sulphonic
acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-
(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide and 2-
pyridylcarbonyl azide there is obtained 2-[6-(1,3-benzodioxol-5-
10 ylsulphonylamino)-5-(2-chloro-5-methoxy-phenoxy)-2-(2-1H-
tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-
ylcarbamate.

Example 52

15 In analogy to Example 4, from 5-isopropyl-pyridine-2-
sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-
ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-
amide there is obtained 2-[5-(2-chloro-5-methoxy-phenoxy)-6-
20 (5-isopropyl-pyridin-2-ylsulphonylamino)-2-(2-1H-tetrazol-5-
yl-pyridin-2-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-yl-
carbamate.

Example 53

25 In analogy to Example 4, from 4-tert-butyl-N-[6-(2-
hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-(1H-tetrazol-5-
yl)-pyridin-2-yl]-pyrimidin-4-yl]-benzenesulphonamide there is
obtained 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-
30 methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-
pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate.

Example 54

35 In analogy to Example 1, from benzyloxy-ethanol Na with 4-
[4-(4-tert-butyl-phenylsulphonylamino)-6-chloro-5-(2-methoxy-
phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide there is obtained N-
[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-

pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide of melting point 170-171 °C from CH₃CN and therefrom with trimethylsilyl cyanide in boiling triethylamine in analogy to Example 1, paragraph a), there is obtained N-[6-(2-benzyloxy-ethoxy)-2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide.

Example 55

10 In analogy to Example 3, from N-[6-(2-benzyloxy-ethoxy)-2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphon-
15 amide as an amorphous substance of melting point 173-175°C.

Example 56

In analogy to Example 1, from benzyloxy-ethanol sodium and
20 5-methyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-amide, melting point 206-208°C from CH₃CN, and
25 therefrom with trimethylsilyl cyanide in boiling triethylamine in analogy to Example 2 there is obtained the corresponding nitrile, 5-methylpyridine-2-sulphonic acid-N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-amide.

30

Example 57

In analogy to Example 3, from the nitrile of Example 56 there is obtained 5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-amide, melting point 202-204°C from CH₃CN.

Example 58

In analogy to Example 1, from benzyloxy-ethanol sodium and 5-isopropyl-pyridine-2-sulphonic acid 6-chloro-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-amide and therefrom with trimethylsilyl cyanide in boiling triethylamine in analogy to Example 2 there is obtained the corresponding nitrile, 5-isopropylpyridine-2-sulphonic acid N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-amide.

Example 59

In analogy to Example 3, from 4-isopropyl-N-[2-(2-cyanopyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide there is obtained 5-isopropyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl]-amide of melting point 236-237°C from CH₃CN.

Example 60

In analogy to Example 2, from 4-tert-butyl-N-[5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-6-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide with trimethylsilyl cyanide in triethylamine there is obtained 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide.

Example 61

In analogy to Example 3, from 4-tert-butyl-N-[2-(2-cyanopyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert-butyl-N-[5-(2-methoxy-phenoxy)-6-[2-(tetra-

hydro-pyran-2-yloxy)-ethoxy]-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide.

Example 62

5

In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the
10 corresponding iminoether and therefrom with NH_4Cl in CH_3OH at room temperature there is obtained 4-tert-butyl-N-[2-[2-(amino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

Example 63

15

In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the
20 corresponding iminoether and therefrom with $\text{NH}_2\text{OH}\cdot\text{HCl}$ in CH_3OH at room temperature there is obtained 4-tert-butyl-N-[2-[2-(hydroxyamino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

25

Example 64

In analogy to Example 6, from 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained the
30 corresponding iminoether and therefrom with 3N HCl at room temperature there is obtained ethyl 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylate.

35

Example 65

By treating the ester prepared in Example 64 with 1N methanolic sodium hydroxide solution at room temperature and

acidifying the reaction solution with acetic acid there is obtained the corresponding 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylic acid.

5

Example 66

a) In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide and ethylene glycol sodium salt there is obtained 4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide as a white product of melting point 197-198°C from EtOAc.

15

Preparation of the starting material:

In analogy to Example 1 b), from 1,3-dicyanobenzene and sodium methylate in methanol followed by ammonium chloride there is obtained 3-cyano-benzamidine hydrochloride and therefrom with diethyl (2-methoxy-phenoxy)malonate there is obtained rac.-3-[5-(2-methoxy-phenoxy)-4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-2-yl]-benzonitrile as a white product. From this compound with PCl_5 and POCl_3 there is obtained 3-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-benzonitrile with a melting point of 155-156° from EtOAc. Reaction with 4-tert.-butylbenzenesulphonamide K yields 4-tert.-butyl-N-[6-chloro-2-(3-cyanophenyl)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

25
30

Example 67

In analogy to Example 3, from 4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide as a solid.

35

Example 68

In analogy to Example 4, from 4-tert.-butyl-N-[6-(2-
5 hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-
phenyl)-pyrimidin-4-yl]-benzenesulphonamide and α -pyridyl-
carbonyl azide there is obtained 2-[6-(4-tert.-butyl-phenyl-
sulphonyl)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-
phenyl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate of
10 melting point 138-139°C.

Example 69

In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-
15 (3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-
benzenesulphonamide and benzyloxy-ethanol sodium salt there is
obtained N-[6-(2-benzyloxy-ethoxy)-2-(3-cyano-phenyl)-5-(2-
methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzene-
sulphonamide as a solid material of melting point 120-122°C
20 from EtOAc.

Example 70

In analogy to Example 3, from N-[6-(2-benzyloxy-ethoxy)-
25 2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-
tert.-butyl-benzenesulphonamide, sodium azide and ammonium
chloride in DMF there is obtained N-[6-(2-benzyloxy-ethoxy)-5-
(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-
4-yl]-4-tert.-butyl-benzenesulphonamide as a light yellow foam.
30

Example 71

In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-
(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-
35 benzenesulphonamide and ethylene glycol sodium salt there is
obtained 4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-
ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-

sulphonamide as a light brownish material of melting point 169-170°C from EtOAc.

Preparation of the starting material:

5

From 1,4-dicyanobenzene and sodium methylate in methanol followed by ammonium chloride there is obtained 4-cyano-benz-amidine hydrochloride, which is used in the next step without further purification, and therefrom with diethyl (2-methoxy-10 phenoxy)-malonate there is obtained rac.-4-[5-(2-methoxy-phenoxy)-4,6-dioxo-1,4,5,6-tetrahydro-pyrimidin-2-yl]-benzo-nitrile as a yellow product with a melting point >250°C. With PCl_5 and POCl_3 this compound yields 4-[4,6-dichloro-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-benzonitrile as a brownish 15 material of melting point 179-180°C from EtOAc. Reaction with 4-tert.-butyl-benzenesulphonamide K finally yields 4-tert.-butyl-N-[6-chloro-2-(4-cyanophenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

20

Example 72

In analogy to Example 3, from 4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide, sodium azide and ammonium 25 chloride in DMF there is obtained 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide as a white material.

Example 73

30

In analogy to Example 1, from 4-tert.-butyl-N-[6-chloro-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide with benzyloxyethanol sodium salt there is obtained N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzene- 35 sulphonamide of melting point 158-159°C from EtOAc.

Example 74

In analogy to Example 3, from N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide, sodium azide and ammonium chloride in DMF there is obtained N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butyl-benzenesulphonamide as a foam.

10

Example 75

a) A solution of 2.1 g (3.4 mmol) of 4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide in 40 ml of abs. THF is treated with 2 ml of 1-(tert.-butyl-dimethylsilyl)-imidazole and heated to 50° while stirring for one hour. The solution is evaporated under reduced pressure and the residue is recrystallized from methylene chloride and isopropyl ether. There is thus obtained 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-ethoxy]-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide of melting point 237-239°C with decomposition.

b) A solution of 366.5 mg (0.5 mmol) of 4-tert.-butyl-N-[6-[2-tert.-butyl-dimethyl-silanyloxy)-ethoxy]-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide in 30 ml of abs. THF is treated at room temperature with 112.2 mg (1 mmol) of potassium tert.-butylate and the suspension is heated at 40°C while stirring for 30 min. 1 ml of ethyl bromide is added to the clear solution and the solution is heated at 40°C for 4 days. Thereafter, the solution is evaporated under reduced pressure, the residue is taken up in a 1:1 mixture of methylene chloride and ether and the organic solution is washed three times with 0.5N NaHCO₃ and thereafter with water. The organic extracts are dried with sodium sulphate and evaporated under reduced pressure. The residue is chromatographed on silica gel with cyclohexane-EtOAc 1:1. Firstly there are isolated 100 mg of 4-tert.-butyl-N-[6-[2-

(tert.-butyl-dimethyl-silanyloxy)-ethoxy-2-[2-(2-ethyl-2H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide and thereafter 100 mg of 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-2-[2-(1-ethyl-1H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide.

c) A solution of 90 mg of 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-ethoxy-2-[2-(2-ethyl-2H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide in 4 ml of CH₃CN-H₂O 1:1 is treated with 5 drops of trifluoroacetic acid and left at room temperature for 24 hours. Thereafter, acetonitrile is evaporated at 30°C under reduced pressure and the aqueous phase is treated firstly with 1N NaOH, then with glacial acetic acid to pH 4 and extracted with ether. The organic extracts are washed with H₂O, dried with sodium sulphate and evaporated under reduced pressure. There is thus obtained 4-tert.butyl-N-[2-[2-(2-ethyl-2H-tetrazol-5-yl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide as a yellowish foam. Analogously, from 4-tert.-butyl-N-[6-[2-(tert.-butyl-dimethyl-silanyloxy)-2-[2-(1-ethyl-1H-tetrazol-5-yl)-pyridin-4-yl]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide there is obtained 4-tert.butyl-N-[2-[2-(1-ethyl-1H-tetrazol-5-yl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]benzenesulphonamide as a yellowish foam.

Example A

Tablets containing the following ingredients can be produced in a conventional manner:

5	<u>Ingredients</u>	<u>Per tablet</u>
	Compound of formula I	10.0 - 100.0 mg
	Lactose	125.0 mg
10	Corn starch	75.0 mg
	Talc	4.0 mg
	Magnesium stearate	1.0 mg

Example B

15 Capsules containing the following ingredients can be produced in a conventional manner:

20	<u>Ingredients</u>	<u>Per capsule</u>
	Compound of formula I	25.0 mg
	Lactose	150.0 mg
	Corn starch	20.0 mg
	Talc	5.0 mg

25

Example C

Injection solutions can have the following composition:

30	a) Compound of formula I, e.g. 4-tert.butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl]-benzenesulphonamide disodium salt	3.0 mg
35	Gelatine	150.0 mg
	Water for injection solutions	ad 1.0 ml

- b) Compound of formula I, e.g.
5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide disodium salt 5.0 mg
5 Gelatine 150,0 mg
Water for injection solutions ad 1.0 ml


- c) Compound of formula I, e.g.
10 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide disodium salt 5.0 mg
Gelatine 150.0 mg
15 Water for injection solutions ad 1.0 ml

Example D

- 20 500 mg of compound of formula I are suspended in 3.5 ml of Myglyol 812 and 0.08 g of benzyl alcohol. This suspension is filled into a container having a dosage valve. 5.0 g of Freon 12 are filled into the container under pressure through the valve. The Freon is dissolved in the Myglyol-benzyl alcohol mixture by
25 shaking. This spray container contains about 100 single doses which can be applied individually.

Claims

1. Compounds of the formula



wherein

R¹ signifies aryl or heterocyclyl;

R² signifies tetrazolyl, lower-alkyl-substituted tetrazolyl, cyano, carboxy, lower-alkoxycarbonyl, hydroxymethyl, formyl, carbamoyl, thiocarbamoyl, amidino or hydroxyamidino;

R³ signifies a residue -O-(CR^aR^b)_n-OR⁹;

R⁴-R⁸ signify hydrogen, lower-alkoxy or halogen;

R⁹ signifies hydrogen, aryl, lower-alkyl, heterocyclyl or a residue -C(O)NHR¹⁰;

R¹⁰ signifies lower-alkyl, phenyl, substituted phenyl, pyridyl or substituted pyridyl;

R^a and R^b signify hydrogen or lower-alkyl;

n signifies 2, 3 or 4; and

A and B signify CH; or one of the symbols A or B signifies nitrogen and the other signifies CH; or

R² signifies hydrogen and one of the symbols A or B signifies N-oxide (N→O) and the other signifies CH,

and pharmaceutically usable salts of compounds of formula I.

2. Compounds according to claim 1, in which R⁹ signifies hydrogen, benzyl, ring-substituted benzyl or a residue -C(O)NHR¹⁰ and the remaining symbols have the significance set forth in claim 1.

3. Compounds according to claim 1 or claim 2, in which A and B are CH.

4. Compounds according to claim 1 or claim 2, in which one of the symbols A or B is nitrogen.
5. Compounds according to claim 1 or claim 2, in which A is nitrogen and B is CH.
6. Compounds according to any one of claims 1-5, in which R² is a tetrazolyl residue.
7. Compounds according to any one of claims 1-6, in which R¹ is a phenyl residue, which is mono- or di-substituted, or a pyridyl residue, which is mono-substituted by alkyl, R³ is -O(CH₂)_nOH, -O(CH₂)_nO-benzyl or -O(CH₂)_nOC(O)NHR¹⁰ and n is 2.
8. Compounds according to any one of claims 1-7, in which R⁴ is lower-alkoxy and R⁵-R⁸ are hydrogen; or R⁴ is halogen, R⁷ is lower-alkoxy and R⁵, R⁶ and R⁸ are hydrogen.
9. The compounds according to claim 6,
- 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,
- 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide.
10. The compounds according to claim 6,
- 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
- 2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl-oxy]-ethyl pyridin-2-ylcarbamate,
- N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzene-sulphonamide,

5 N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzenesulphonamide,

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide,

10 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,

15 N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzenesulphonamide,

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzolsulphonamide,

20 pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-ylamide,

4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,

25 1,3-benzodioxol-5-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide,

30 5-isopropyl-pyridine-2-sulphonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amide,

4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[6-(1H-tetrazol-5-yl)-pyridin-2-yl]-pyrimidin-4-yl]-benzenesulphonamide,

35 2-[5-(2-methoxy-phenoxy)-6-phenylsulphonylamino-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,

2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-

- yl oxy]-ethyl pyridin-2-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methyl-phenylsulphonyl-
amino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-
yl oxy]-ethyl 1,3-benzodioxol-5-yl carbamate,
- 5 2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonyl-
amino)-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yl oxy]-
ethyl pyridin-2-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methoxy-phenylsulphonyl-
amino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-
10 yl oxy]-ethyl 1,3-benzodioxol-5-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-(4-methylsulphanylphenyl-
sulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yl oxy]-ethyl pyridin-2-yl carbamate
2-[6-(1,3-benzodioxol-5-ylsulphonylamino)-5-(2-methoxy-
15 phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-
yl oxy]-ethyl pyridin-2-yl carbamate,
2-[6-(1,3-benzodioxol-5-ylsulphonylamino)-5-(2-methoxy-
phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-
yl oxy]-ethyl 1,3-benzodioxol-5-yl carbamate,
- 20 2-[6-(3,4-dimethoxy-phenylsulphonylamino)-5-(2-
methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yl oxy]-ethyl pyridin-2-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-(2,5-dimethoxy-phenyl-
sulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
25 pyrimidin-2-yl oxy]-ethyl pyridin-2-yl carbamate,
2-[5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-
4-yl)-6-pyridin-3-ylsulphonylamino-pyrimidin-4-yl oxy]-ethyl
pyridin-2-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-pyridin-3-ylsulphonylamino-
30 2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl oxy]-ethyl
1,3-benzodioxol-5-yl carbamate,
2-[5-(2-methoxy-phenoxy)-6-(5-methyl-pyridin-2-yl-
sulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yl oxy]-ethyl pyridin-2-yl carbamate,
- 35 2-[6-(5-isopropyl-pyridin-2-ylsulphonylamino)-5-(2-
methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yl oxy]-ethyl pyridin-2-yl carbamate
2-[6-(5-isopropyl-pyridin-2-ylsulphonylamino)-5-(2-

methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yloxy]-ethyl 1,3-benzodioxol-5-ylcarbamate,
2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-chloro-5-
methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
5 pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[6-(1,3-benzodioxol-5-ylsulphonylamino)-5-(2-chloro-5-
methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[5-(2-chloro-5-methoxy-phenoxy)-6-(5-isopropyl-
10 pyridin-2-ylsulphonylamino)-2-(2-1H-tetrazol-5-yl-pyridin-2-
yl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,
2-[6-(4-tert-butyl-phenylsulphonylamino)-5-(2-methoxy-
phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-
yloxy]-ethyl pyridin-2-ylcarbamate,
15 N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(2-
1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-butyl-
benzenesulphonamide,
5-methyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-
ethoxy)-5-(2-methoxy-phenoxy)-2-(2-1H-tetrazol-5-yl-pyridin-
20 4-yl]-amide,
5-isopropyl-pyridine-2-sulphonic acid [6-(2-benzyloxy-
ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-
pyridin-4-yl]-pyrimidin-4-yl]-amide,
4-tert-butyl-N-[5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-
25 pyran-2-yloxy)-ethoxy]-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-
pyrimidin-4-yl]-benzenesulphonamide,
4-tert-butyl-N-[2-[2-(1-ethyl-1H-tetrazol-5-yl)-pyridin-
4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-
4-yl]benzenesulphonamide.

30

11. The compounds according to claim 2,

4-tert.-butyl-N-[2-(3-cyano-phenyl)-6-(2-hydroxy-
ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-
35 benzenesulphonamide,
4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-
phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-
benzenesulphonamide,

2-[6-(4-tert.-butyl-phenylsulphonyl)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yloxy]-ethyl pyridin-2-ylcarbamate,

5 N-[6-(2-benzyloxy-ethoxy)-2-(3-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butylbenzenesulphonamide,

N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(3-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butylbenzenesulphonamide,

10 4-tert.-butyl-N-[2-(4-cyano-phenyl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,

4-tert.-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-benzenesulphonamide,

15 N-[6-(2-benzyloxy-ethoxy)-2-(4-cyano-phenyl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert.-butylbenzenesulphonamide,

20 N-[6-(2-benzyloxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(4-1H-tetrazol-5-yl-phenyl)-pyrimidin-4-yl]-4-tert.-butylbenzenesulphonamide.

12. The compounds according to claim 3,

25 4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,

N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,

30 N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylbenzenesulphonamide,

N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methoxybenzenesulphonamide,

35 N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-methylsulphanylbenzenesulphonamide,

1,3-benzodioxol-5-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,

5 N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-3,4-dimethoxy-benzene-sulphonamide,

N-[2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-2,5-dimethoxy-benzene-sulphonamide,

10 pyridine-3-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,

5-methyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,

15 5-isopropyl-pyridine-2-sulphonic acid 2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-ylamide,

4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-yl]-benzenesulphonamide,

20 1,3-benzodioxol-5-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide,

25 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-2-(2-cyano-pyridin-4-yl)-6-(2-hydroxy-ethoxy)-pyrimidin-4-ylamide,

4-tert-butyl-N-[2-(6-cyano-pyridin-2-yl)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzene-sulphonamide,

30 N-[6-(2-benzyloxy-ethoxy)-2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulphonamide,

5-isopropyl-pyridine-2-sulphonic acid-N-[6-(2-benzyloxy-ethoxy)-2-(2-cyanopyridin-4-yl)-5-(2-methoxyphenoxy)-

35 pyrimidin-4-yl]-amide,

4-tert-butyl-N-[2-(2-cyano-pyridin-4-yl)-5-(2-methoxy-phenoxy)-6-[2-(tetrahydro-pyran-2-yl)-ethoxy]-pyrimidin-4-yl]-benzenesulphonamide,

4-tert-butyl-N-[2-[2-(amino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,

5 4-tert-butyl-N-[2-[2-(hydroxyamino-imino-methyl)-pyridin-4-yl]-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-benzenesulphonamide,

ethyl 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylate,

10 4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine-2-carboxylic acid.

13. The compounds according to claim 1,

15

4-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide,

20 N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methyl-benzene-sulphonamide,

25 N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methoxy-benzene-sulphonamide,

N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-4-methylsulphanyl-benzenesulphonamide,

30 1,3-benzodioxol-5-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,

35 N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimethoxy-benzene-sulphonamide,


N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimethoxy-benzene-sulphonamide,

- pyridine-3-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
 5-methyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
 5-isopropyl-pyridine-2-sulphonic acid 6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
 4-tert-butyl-N-[5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-yl]-benzenesulphonamide,
 1,3-benzodioxol-4-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
 5-isopropyl-pyridine-2-sulphonic acid 5-(2-chloro-5-methoxy-phenoxy)-6-(2-hydroxy-ethoxy)-2-(1-oxy-pyridin-4-yl)-pyrimidin-4-ylamide,
 2-[4-(4-tert-butyl-phenylsulphonylamino)-6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-pyrimidin-2-yl]-pyridine 1-oxide.

14. Pharmaceutical preparations, especially for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris, containing a compound of any one of claims 1-13 and usual carrier materials and adjuvants.

15. A process for the manufacture of compounds of any one of claims 1-13, which process comprises

- a) reacting a compound of formula II




II

wherein R^{12} is 3- or 4-cyanophenyl or 2- or 4-pyridyl N-oxide and Hal is halogen and the remaining symbols have the significance set forth above,

with a compound of the formula $MO-(CR^aR^b)_n-OR^{91}$, wherein M is an alkali metal and R^{91} is hydrogen, aryl, lower-alkyl or heterocyclyl and R^a , R^b and n have the significance set forth above; or

b) reacting a compound of formula III



wherein R^{11} is 2- or 4-pyridyl N-oxide and the remaining symbols have the significance set forth above,

15 with a trialkylsilyl cyanide and a trialkylamine; or

c) reacting a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above with an azide in the presence of an aprotic Lewis acid; or

20

d) converting a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above with an alkali metal alcoholate and thereafter with hydrazine into the corresponding amidrazone and treating this with a nitrite and an acid; or

25

e) reacting a compound of formula I in which R^9 is hydrogen with an isocyanate of the formula $R^{10}NCO$; or

30 f) transforming the cyano group in a compound of formula I in which R^2 is cyano and the remaining symbols have the significance set forth above into an amidino, carbamoyl, thiocarbamoyl, lower-alkoxycarbonyl, carboxy, hydroxymethyl, formyl or hydroxyamidino group; or

35

g) alkylating the tetrazolyl group in a compound of formula I in which R² is tetrazolyl and R⁹ is a hydroxy protecting group, benzyl or ring-substituted benzyl and cleaving off a hydroxy protecting group from the reaction product;

5

and, if desired, converting a compound of formula I obtained into a salt.

16. The compounds of any one of claims 1-13 for use as medicaments, especially for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.

17. The use of compounds of any one of claims 1-13 as active ingredients for the production of medicaments for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders such as hypertension, ischaemia, vasospasms and angina pectoris.

20

18. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

 Internat. Application No
 PCT/EP 95/04843

 A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D239/69 C07D401/14 C07D401/12 C07D403/10 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 510 526 (HOFFMAN LA ROCHE) 28 October 1992 see the whole document ---	1,14-17
A	EP,A,0 526 708 (HOFFMAN LA ROCHE) 10 February 1993 see the whole document ---	1,14-17
P,X	EP,A,0 633 259 (HOFFMAN LA ROCHE) 11 January 1995 see claims ---	1,14-17
P,X	EP,A,0 658 548 (TANABE SEIYAKU) 21 June 1995 see claims -----	1,14-17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

22 March 1996

Date of mailing of the international search report

2.04.96

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 95/04843

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-510526	28-10-92	AU-B- 652238	18-08-94
		AU-B- 1497692	29-10-92
		CA-A- 2067288	26-10-92
		JP-A- 5155864	22-06-93
		JP-B- 6070021	07-09-94
		NZ-A- 242396	22-12-94
		US-A- 5270313	14-12-93

EP-A-526708	10-02-93	AU-B- 653604	06-10-94
		AU-B- 1812192	17-12-92
		CA-A- 2071193	14-12-92
		JP-A- 5222003	31-08-93
		JP-B- 7030042	05-04-95
		NZ-A- 243074	25-11-94
		US-A- 5292740	08-03-94

EP-A-633259	11-01-95	AU-B- 6594894	05-01-95
		BG-A- 98880	31-05-95
		BR-A- 9402558	28-03-95
		CA-A- 2125730	29-12-94
		CN-A- 1106007	02-08-95
		CZ-A- 9401573	18-01-95
		FI-A- 943084	29-12-94
		HU-A- 67636	28-04-95
		JP-A- 7017972	20-01-95
		LT-A,B 1979	31-01-95
		NO-A- 942428	29-12-94
		PL-A- 304007	09-01-95
		SK-A- 77994	08-03-95
		ZA-A- 9404434	03-01-95

EP-A-658548	21-06-95	AU-B- 8046194	22-06-95
		CA-A- 2137953	18-06-95
		CN-A- 1111242	08-11-95
		FI-A- 945900	18-06-95
